|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Alcoholic liver disease显示文摘Alcohol use disorders affect millions of individuals worldwide.Alcohol consumption is directly associated with liver disease mortality and accounts for elevated social and economic costs.Alcoholic liver disease(ALD) may take the form of acute involvement(alcoholic hepatitis)or chronic liver disease(steatosis,steatohepatitis,fibrosis and cirrhosis).The severity and prognosis of alcohol-induced liver disease depends on the amount,pattern and duration of alcohol consumption,as well as on the presence of liver inflammation,diet,nutritional status and genetic predisposition of an individual.While steatosis is an almost completely benign disease,liver cirrhosis is associated with marked morbidity,mortal-ity and life expectancy shortening.The median survival of patients with advanced cirrhosis is 1-2 years.Se-vere acute alcoholic hepatitis(AH)is associated with mortality as high as 50%.It has been managed with corticoids,pentoxifylline and enteral nutrition,although evidence based data are still conflicting.Some author suggest that pentoxifylline could be a better first-line treatment in patients with severe AH.Absolute abstinence is a basic condition for any treatment of acute or chronic ALD,the other therapeutical procedure being of a supportive nature and questionable significance.Acamprosate appears to be an effective treatment strategy for supporting continuous abstinence in alco-hol dependent patients.Patients with advanced liver cirrhosis who demonstrably abstain can be considered for liver transplantation,which leads to a markedly pro-longed life expectancy.The crucial step in ALD preven-tion is in the prevention of alcohol abuse,whereas the prevention of liver injury in active alcohol abusers is not clinically applicable. | Radan Bruha Karel Dvorak Jaromir Petrty | 2012 | World Journal of Hepatology2012，4，3： | 28 |
| 2 | Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis显示文摘AIM: To investigate the relationship between osteopontin plasma concentrations and the severity of portal hypertension and to assess osteopontin prognostic value.METHODS: A cohort of 154 patients with confirmed liver cirrhosis(112 ethylic, 108 men, age 34-72 years)were enrolled in the study. Hepatic venous pressure gradient(HVPG) measurement and laboratory and ultrasound examinations were carried out for all patients. HVPG was measured using a standard catheterization method with the balloon wedge technique. Osteopontin was measured using the enzyme-linked immunosorbent assay(ELISA) method in plasma. Patients were followed up with a specific focus on mortality. The control group consisted of 137 healthy age- and sex- matched individuals.RESULTS: The mean value of HVPG was 16.18 ± 5.6 mm Hg. Compared to controls, the plasma levels of osteopontin in cirrhotic patients were significantly higher(P < 0.001). The plasma levels of osteopontin were positively related to HVPG(P = 0.0022, r = 0.25) and differed among the individual Child-Pugh groups of patients. The cut-off value of 80 ng/m L osteopontin distinguished patients with significant portal hypertension(HVPG above 10 mm Hg) at 75% sensitivity and 63% specificity. The mean follow-up of patients was 3.7 ± 2.6 years. The probability of cumulative survival was 39% for patients with HVPG > 10 mm Hg and 65% for those with HVPG ≤ 10 mm Hg(P = 0.0086, odds ratio(OR), 2.92, 95% confidence interval(CI): 1.09-7.76). Osteopontin showed a similar prognostic value to HVPG. Patients with osteopontin values above 80 ng/m L had significantly lower cumulative survival compared to those with osteopontin ≤ 80 ng/m L(37% vs 56%, P = 0.00035; OR = 2.23, 95%CI: 1.06-4.68).CONCLUSION: Osteopontin is a non-invasive parameter of portal hypertension that distinguishes patients with clinically significant portal hypertension. It is a strong prognostic factor for survival. | Radan Bruha Marie Jachymova Jaromir Petrtyl Karel Dvorak Martin Lenicek Petr Urbanek Tomislav Svestka Libor Vitek | 2016 | World Journal of Gastroenterology2016，22，12： | 20 |
| 3 | Long term pharmacological treatment of portal hypertension显示文摘 | Bruha R Petrtyl J Urbanek P | 2005 | Cas LEK Cesk2005，144，： | 1 |
| 4 | Intraluminal brachytherapu and selfexpandable stents in nonrescetable biliary malignancies the question of long-term palliation显示文摘 | Bruha R Petrlyl J Kubeeova M | 2001 | Hepato-Gastroenterology2001，48，： | 1 |
| 5 | Alcoholic liver disease显示文摘 | Bruha R Dvorak K Dousa M | 2011 | Praque Med Rep2011，110，3： | 1 |
| 6 | Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes显示文摘 | BRUHA R VITEK L PETRTYL J | 2006 | Scand J Gastroen- terol2006，41，12： | 1 |
| 7 | Intraluninal brachytherapy and selfexpandable stents in nonresectable billary malignancies - the question of long - term paliation 显示文摘 | Bruha R Petrtyl J Kubecova M | 2001 | Hepatogastroenterology2001，18，39： | 1 |
| 8 | Alcoholic liver disease显示文摘 | Bruha R Dvorak K Dousa M | 2009 | Praque Med Rep2009，110，3： | 1 |
| 9 | Intraluminal brachytherapy and selfexpandable stents in nonresectable biliary malignancies the question of long-term palliation显示文摘 | Bruha R Petrty I Kubecova M | 2001 | Heptao Gastroenterol2001，48，5： | 1 |
| 10 | Discretization and Grouping:Preprocessing Steps for Data Mining显示文摘 | Berka P Bruha I | 1998 | Principles of Data Mining and Knowledge Discovery1998，，： | 1 |
| 11 | Intraluminal brachytherapy and selfexpand-able stents in nonresectable biliaty malignancies - - the question of long- term palliation显示文摘 | Bruha R Petrtyl J Kubecova M | 2001 | Hepatogasroenterology2001，48，39： | 1 |
| 12 | Double-blind randomized multicenter study comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices显示文摘 | Bruha R Marecek Z Prochazka V | 2009 | Hepatogastroenterology2009，56，90： | 1 |
| 13 | Sleep disorders in Wilson' s disease 显示文摘 | Nevsimalova S Buskova J Bruha R Kemlink D Sonka K Vitek L Marecek Z | 2011 | Display Settings2011，18，1： | 1 |
| 14 | Intraluminal brachytherapy and selfexpandable stents in nonresectable biliary malignancies-the question of long - term palliation 显示文摘 | Bruha R Petrtyl J Kubecova M | 2001 | Hepatogastroenterology2001，48，： | 1 |
| 15 | Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes显示文摘 | BRUHA R VITEK L PETRTYL J | 2006 | Scand J Gastroenterol2006，41，12： | 1 |
| 16 | Management of benign intrahepatic bile duct strictures : initial experience with polydioxanone biodegradable stents 显示文摘 | Petrtyl J Bruha R Horak L | 2010 | Endoscopy2010，422，： | 1 |
| 17 | Double-blind randomized multicenter study comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices显示文摘 | Bruha R Marecek Z Prochazka V | 2009 | Hepatogastroenterology2009，56，90： | 1 |
| 18 | Intraluminal brachytherapy and selfexpandable stents in nonreseetable biliary malignancies-the question of long-term palliation显示文摘 | Bruha R Petrtyl I Kubeeova M | 2001 | Hepa Togastroenterology2001，48，39： | 1 |
| 19 | Intraluminal brachytherapy and selfexpandable stents in nonrescetable biliary malignancies the question of long-trem palliation显示文摘 | Bruha R Petrtyl J Kubeeova M | 2001 | Hepato-Gastroenterology2001，48，69： | 1 |
| 20 | Endoscopic variceal band ligation compared with propranolol for prophylaxis of first variceal bleeding显示文摘 | DRASTICH P LATA J PETRTYL J BRUHA R PROCHAZKA V VANASEK T | 2011 | Ann Hepatol2011，10，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员